Ginkgo Bioworks Holdings (DNA) Operating Income (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Operating Income of -$71.4 million for Q1 2026, down 0.88% on a QoQ basis from -$70.8 million in Q4 2025, and up 11.85% year-over-year from -$63.8 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Operating Income (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Operating Income history runs 7 years deep, the most recent figure standing at -$71.4 million for Q1 2026.
- Quarterly Operating Income rose 11.85% year-over-year to -$71.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$297.7 million (up 35.67% YoY) and the FY2025 annual result came in at -$315.3 million, up 43.68% from the prior year.
- Operating Income was -$71.4 million for Q1 2026 at Ginkgo Bioworks Holdings, down from -$70.8 million in the prior quarter.
- Across five years, Operating Income topped out at -$55.2 million in Q3 2024 and bottomed at -$675.4 million in Q1 2022.
- A 5-year average of -$236.0 million and a median of -$178.1 million in 2023 frame the typical range for Operating Income.
- Peak annual rise in Operating Income reached 86.3% in 2022, while the deepest fall reached 2355.53% in 2022.
- Ginkgo Bioworks Holdings' Operating Income stood at -$230.9 million in 2022, then gained by 22.85% to -$178.1 million in 2023, then surged by 41.83% to -$103.6 million in 2024, then surged by 31.71% to -$70.8 million in 2025, then declined by 0.88% to -$71.4 million in 2026.
- Business Quant data shows DNA's Operating Income at -$71.4 million in Q1 2026, -$70.8 million in Q4 2025, and -$90.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -71.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.37 Mn |
| Dec 31, 2025 | -70.75 Mn |
| Sep 30, 2025 | -90.02 Mn |
| Jun 30, 2025 | -65.54 Mn |
| Mar 31, 2025 | -80.97 Mn |
| Dec 31, 2024 | -103.61 Mn |
| Sep 30, 2024 | -55.20 Mn |
| Jun 30, 2024 | -222.95 Mn |
| Mar 31, 2024 | -178.00 Mn |
| Dec 31, 2023 | -178.12 Mn |
| Sep 30, 2023 | -286.39 Mn |
| Jun 30, 2023 | -184.15 Mn |
| Mar 31, 2023 | -215.75 Mn |
| Dec 31, 2022 | -230.86 Mn |
| Sep 30, 2022 | -654.94 Mn |
| Jun 30, 2022 | -647.78 Mn |
| Mar 31, 2022 | -675.37 Mn |
| Dec 31, 2021 | -1.68 Bn |
| Sep 30, 2021 | -26.67 Mn |
| Jun 30, 2021 | -59.95 Mn |